Biomarkers of Relapse In ulcerative colitis patients after Tofacitinib dose rEduction (BRITE)
Latest Information Update: 07 Nov 2023
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Biomarker; Pharmacodynamics
- Acronyms BRITE
- 10 Oct 2023 Status changed from active, no longer recruiting to completed.
- 15 Sep 2023 Status has been changed to active, no longer recruiting.
- 08 Jun 2023 Planned End Date changed from 5 Jun 2023 to 1 Sep 2023.